Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
NCT06685692
Recruiting
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/28/2025
Locations: Bon Secours Liver Institute of Newport News, Richmond, Virginia
Conditions: Alcohol Hepatitis
Register for Updates
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
NCT05636618
Recruiting
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/28/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Small-cell Lung Cancer
Register for Updates
Bright Ideas - CIN Feasibility Study
NCT04929899
Recruiting
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
01/28/2025
Locations: Inova Children's Hospital, Falls Church, Virginia
Conditions: Acute Lymphoblastic Leukemia (ALL)
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia
Conditions: Solid Tumors
Register for Updates
Automated Insulin Delivery for Inpatients with Dysglycemia
NCT06418880
Recruiting
This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the efficacy and safety of AID versus multiple daily insulin injections (MDI) + CGM in the inpatient setting * To determine differences in CGM-derived metrics between AID and MDI plus CGM in the hospital and e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Virginia School of Medicine, Charlottesville, Virginia
Conditions: Type 1 Diabetes, Type 2 Diabetes
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Inova Schar Cancer Center, Fairfax, Virginia
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Oncology & Hematology Associates of Southwest Virginia, Roanoke, Virginia
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Register for Updates
Characterization of the Pudendal Nerve with Transvaginal Ultrasonography
NCT06021782
Recruiting
This is a feasibility study characterizing the ability of transvaginal ultrasonography to identify the pudendal nerve. Today, the pudendal nerve block is typically accomplished through blind landmark techniques, thus limiting its success. To date, there has never been an attempt to determine if the visualization of the pudendal nerve would be possible using transvaginal ultrasound with existing technology; nor to perform this procedure transvaginally with the assistance of ultrasound.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/26/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Anesthesia
Register for Updates
Pessary Experience Study
NCT06021769
Recruiting
Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately planning surgery. Most studies suggest that about 75% of patients are able to be successfully fit with a pessary, but about 50% discontinue pessary use within 12 months of initiation. The purpose of th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/26/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Pelvic Organ Prolapse, Stress Urinary Incontinence
Register for Updates
Reduction in Number of Botox Injections for Urgency Urinary Incontinence
NCT04731961
Recruiting
The overall objective of this study is to determine if a reduced injection site protocol (5 injection sites) using an equivalent amount of Botox provides comparable relief of Urgency Urinary Incontinence (UUI) symptoms compared to the standard injection site protocol (15-20 injection sites). Our central hypothesis is that the 5-site injection protocol is non-inferior in terms of relief of UUI symptoms compared to the standard injection site protocol, measured by a non-inferior reduction in the n... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
01/26/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Urgency Urinary Incontinence
Register for Updates
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774
Recruiting
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/24/2025
Locations: Next Oncology, Fairfax, Virginia
Conditions: Advanced Solid Tumor
Register for Updates
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423
Recruiting
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) dise... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates